• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    AstraZeneca PLC - American Depositary Shares (NY:AZN)

    188.20 +2.42 (+1.30%)
    Streaming Delayed Price Updated: 12:01 PM EDT, Mar 25, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 506,916
    Open 187.67
    Bid (Size) 188.10 (400)
    Ask (Size) 188.20 (100)
    Prev. Close 185.78
    Today's Range 186.44 - 188.24
    52wk Range 182.39 - 212.71
    Shares Outstanding N/A
    Dividend Yield 0.49%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Merck & Co. (MRK) 2026 Analysis: Navigating the Keytruda Cliff with Pipeline-Driven Resilience
    As of March 25, 2026, Merck & Co., Inc. (NYSE: MRK) stands at a pivotal crossroads in its 135-year history. Known globally as a titan of oncology and vaccines, the Rahway, New Jersey-based... 
    Via Finterra
    Topics Artificial Intelligence Economy Intellectual Property
    News headline image
    The Great Unbundling: How AI’s Insatiable Hunger is Driving a Corporate Divestiture Gold Rush
    As of March 18, 2026, the corporate landscape has undergone a radical transformation. The era of the sprawling global conglomerate, once the gold standard of industrial stability, is rapidly giving way... 
    Via MarketMinute
    Topics Artificial Intelligence Economy

    Performance

    YTD
    -0.1%
    -0.1%
    1 Month
    -8.2%
    -8.2%
    3 Month
    -0.1%
    -0.1%
    6 Month
    -0.1%
    -0.1%
    1 Year
    -0.1%
    -0.1%

    More News

    Read More
    News headline image
    Could This International ETF Be One of the Best Investments of 2026? ↗
    Via The Motley Fool
    Topics ETFs
    News headline image
    The 'Sentiment Trap': Why Beating Earnings Is No Longer Enough in the Age of AI Sentiment Analysis
    Via MarketMinute
    Topics Artificial Intelligence Earnings Regulatory Compliance
    News headline image
    The Billion-Dollar Divide: How "Megadeals" Are Defining a K-Shaped M&A Market in 2026
    Via MarketMinute
    Topics Artificial Intelligence Economy Energy
    News headline image
    Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity
    Via Finterra
    Topics Economy Intellectual Property Lawsuit
    News headline image
    AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer
    From AstraZeneca
    Via Business Wire
    News headline image
    ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer
    From AstraZeneca
    Via Business Wire
    News headline image
    The Great Rotation: Why Global Capital is Deserting US Tech for International Value in 2026
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    News headline image
    Compugen (CGEN) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    As Investors Flee U.S. Equities, This Global ETF Is Outperforming ↗
    Via MarketBeat
    Topics ETFs
    News headline image
    After a Near 50% Drop, Tempus AI Could Be Ripe for a Rebound ↗
    Via MarketBeat
    Topics Artificial Intelligence
    News headline image
    Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy
    Via MarketMinute
    Topics Economy Intellectual Property
    News headline image
    AstraZeneca’s Strategic Leap: Pharmaceutical Giant Completes Historic Move to the New York Stock Exchange
    Via MarketMinute
    Topics ETFs
    News headline image
    Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting
    From AstraZeneca
    Via Business Wire
    News headline image
    ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Decade, According to Wall Street Analysts ↗
    Via The Motley Fool
    Topics ETFs Stocks
    News headline image
    The Great 2026 Divergence: Tech Titans Rise on AI Execution While Healthcare Reaps a Regulatory Whirlwind
    Via MarketMinute
    Topics Artificial Intelligence Economy Intellectual Property
    News headline image
    Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine
    From AstraZeneca
    Via Business Wire
    News headline image
    A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH ↗
    Via MarketBeat
    News headline image
    Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance
    Via Finterra
    Topics Economy Intellectual Property
    News headline image
    The Great Rebound: 2026 Becomes the Year of the Strategic Mega-Deal as M&A Activity Surges
    Via MarketMinute
    Topics Artificial Intelligence Economy
    News headline image
    AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US
    From AstraZeneca
    Via Business Wire
    News headline image
    AstraZeneca Signals a New Era in Obesity Care: Earnings Report Teases Oral GLP-1 Powerhouse
    Via MarketMinute
    Topics Artificial Intelligence Earnings Economy

    Frequently Asked Questions

    Is AstraZeneca PLC - American Depositary Shares publicly traded?
    Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.
    What exchange does AstraZeneca PLC - American Depositary Shares trade on?
    AstraZeneca PLC - American Depositary Shares trades on the New York Stock Exchange
    What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?
    The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the New York Stock Exchange
    What is the current price of AstraZeneca PLC - American Depositary Shares?
    The current price of AstraZeneca PLC - American Depositary Shares is 188.20
    When was AstraZeneca PLC - American Depositary Shares last traded?
    The last trade of AstraZeneca PLC - American Depositary Shares was at 03/25/26 12:01 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.